SuperworthEdwards Lifesciences EW
- Market cap
- $51.3B
- PE
- 51.2×
- 10y median 40.3×
- Forward PE
- 28.3×
- 10y median 32.4×
- Price to sales
- 7.9×
- EV/EBIT
- 23.5×
- Revenue, 12 months
- $6.5B
- +15% on a year ago
- Net margin
- 15.4%
- Free cash flow yield
- 2.8%
Edwards Lifesciences trades at 51.2× trailing earnings, pricier than 73% of the last ten years. Revenue was $6.5B over the last twelve months, up 15% on a year earlier with a 15% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.2B−6% | $1.3B−6% | $1.3B+9% | $1.4B+7% | $1.4B+9% | $1.4B+9% | $1.4B+6% | $1.5B+12% | $1.6B+15% | $1.6B+13% | $1.6B+17% | $1.7B+14% | |
| Cost of revenue | $250.6M−1% | $356.9M+38% | $286.9M−13% | $275.5M+7% | $262.9M+5% | $292.2M−18% | $301.6M+5% | $344.4M+25% | $345.2M+31% | $343M+17% | $362.6M+20% | $392.4M+14% |
| Gross profit | $992.8M−7% | $1B−7% | $1B+5% | $1.1B+6% | $1.1B+10% | $1.1B+8% | $1.1B+7% | $1.2B+9% | $1.2B+11% | $1.2B+12% | $1.3B+16% | $1.3B+14% |
| R&D | $242.8M+4% | $270M+16% | $256.7M−2% | $271.8M+12% | $253.4M+4% | $271.1M+0% | $254.6M−1% | $276.2M+2% | $280.7M+11% | $267.7M−1% | $263.3M+3% | $278.9M+1% |
| SG&A | $381.9M+1% | $480M+17% | $428.4M−2% | $447.5M+9% | $421.4M+10% | $491.9M+3% | $465.7M+9% | $502M+12% | $514.6M+22% | $602.9M+23% | $522.2M+12% | $561.2M+12% |
| $365.9M−9% | $400.1M−11% | $349M−10% | $366.5M+39% | $350.6M−4% | $312.6M−22% | $394.8M+13% | $411.2M+12% | $307.1M−12% | $151.1M−52% | $477.6M+21% | $513.2M+25% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | $387.6M−5% | $421.7M−8% | $371.2M−7% | $384M+40% | $402.8M+4% | $390.1M−8% | $433.9M+17% | $400.2M+4% | $348.4M−14% | $90.4M−77% | $459M+6% | $519.8M+30% |
| $52.7M−17% | $52M−15% | $46.3M−20% | $20M−4% | $40.7M−23% | $45.1M−13% | $70.3M+52% | $64.3M+222% | $56.1M+38% | $26.2M−42% | $78.3M+11% | $278.4M+333% | |
| Net income | $384.9M+12% | $369.9M−7% | $351.9M+3% | $366.3M+19% | $3.1B+698% | $385.6M+4% | $358M+2% | $333.2M−9% | $291.1M−91% | $91.2M−76% | $380.7M+6% | $241.9M−27% |
| $0.63+15% | $0.61−6% | $0.58+4% | $0.61+22% | $5.13+714% | $0.65+7% | $0.61+5% | $0.56−8% | $0.50−90% | $0.16−75% | $0.66+8% | $0.42−25% | |
| 609.5M−2% | 607M−2% | 604.1M−1% | 604.3M−1% | 598.1M−2% | 590.7M−3% | 587.8M−3% | 587.9M−3% | 585.7M−2% | 581.6M−2% | 580.7M−1% | 577.6M−2% |
Operating income: 32 periods, Q2 FY09 to Q1 FY17: not printed by the filing, worked out from its own lines.
Net income: 47 periods, Q3 FY11 to Q1 FY23: not printed by the filing, worked out from its own lines.
EPS, diluted: 5 periods, Q4 FY09 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 16 periods, Q4 FY09 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY17: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $1.7B | $1.7B to $1.7B | $0.74 | $0.73 to $0.76 | 16 |
| Q4 FY26 | $1.7B | $1.7B to $1.7B | $0.71 | $0.67 to $0.74 | 16 |
| Q1 FY27 | $1.8B | $1.8B to $1.8B | $0.83 | $0.82 to $0.85 | 8 |
| Q2 FY27 | $1.9B | $1.9B to $1.9B | $0.86 | $0.85 to $0.88 | 7 |
| Q3 FY27 | $1.9B | $1.8B to $1.9B | $0.84 | $0.83 to $0.86 | 7 |
| Q4 FY27 | $1.9B | $1.9B to $1.9B | $0.84 | $0.83 to $0.86 | 12 |
| Q1 FY28 | $2B | $2B to $2B | $0.95 | $0.93 to $0.96 | 9 |
| Q2 FY28 | $2.1B | $2.1B to $2.1B | $0.97 | $0.95 to $0.98 | 8 |
Peers
Companies in Medical - Devices nearest Edwards Lifesciences' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| EWEdwards Lifesciences | $51.3B | 51.2× | 40.3× | 28.3× | 7.9× | +15% | 15.4% |
| BSXBoston Scientific | $66.2B | 18.5× | 67.0× | 14.1× | 3.2× | +14% | 17.5% |
| GEHCGE HealthCare Technologies | $32.3B | 16.4× | 17.0× | 13.8× | 1.5× | +7% | 9.3% |
| DXCMDexCom | $29.4B | 30.9× | 102× | 27.7× | 5.9× | +16% | 20.1% |
| SYKStryker | $117.8B | 31.8× | 41.2× | 19.3× | 4.6× | +8% | 14.4% |
| MDTMedtronic | $122B | 23.4× | 28.2× | 15.9× | 3.3× | +10% | 13.9% |
| ZBHZimmer Biomet | $18.8B | 24.0× | 31.4× | n/m | 2.2× | +9% | 9.5% |
| ABTAbbott Laboratories | $179.4B | 38.7× | 36.7× | 17.7× | n/m | n/m | n/m |
| Peer median | $66.2B | 24.0× | 36.7× | 16.8× | 3.2× | +9% | 14.2% |
Investors who own it
Investors we follow who held Edwards Lifesciences at the end of Jun 30, 2026, from their 13F filings.
- Baillie GiffordBaillie Gifford0.1% of portfolioadded
- Ron BaronBaron Capital0.0% of portfolioadded
More on Edwards Lifesciences
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #4of 17Medical device stocks with the highest profit margins
- #7of 17Medical device stocks with the fastest revenue growth
- #9of 13Medical device stocks with the lowest EV/EBIT
Its groups
About
- Industry
- Medical - Devices
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .